Multiple Sclerosis Therapeutics Market to Score Past US$ 24.4 Billion Valuation by 2025 – Coherent Market Insights
SEATTLE, March 17, 2021, (PHARMIWEB) —
Global Multiple Sclerosis Therapeutics Market
Multiple sclerosis (MS) is a demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord get severely impaired. The disease leads to malfunction of the nervous system, which in turn, causes several signs and symptoms, including physical, mental, and psychiatric issues. Double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination are some of the other symptoms of this disease. Various types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). RPMS is therefore the most common type characterized by defined attacks with increasing neurological symptoms. PPMS is a rare form, which is characterized by gradual progression of the disease, while, SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the condition include partial or complete vision loss, prolonged vision loss, lack of coordination, and slurred speech.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1310
A specific combination of various genetic and environmental factors is responsible for the rising prevalence of the condition. According to a study carried out by the International Progressive Alliance in 2013, MS is two to three times more common in women than in men, which suggests that hormones play a significant role in determining susceptibility to the disease.
The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% throughout the forecast period (2017-2025).
Figure 1. Global Multiple Sclerosis Therapeutics Market (US$ Mn), by Region, 2016
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy-Now this Research Report @ https://bit.ly/3f1C6m7
Increasing prevalence of multiple sclerosis to augment the global market growth
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people belonging to the age group of 20–50 years. According to the Multiple Sclerosis Foundation, this autoimmune condition affects 2.5 million people each year, with the global incidence rate of around 7 cases per 100,000 people. Among regions, North America dominates the global multiple sclerosis therapeutics market, owing to the high prevalence of the condition and the rising economic burden of the disease leading to higher adoption of novel therapeutics. As per the same source, an estimated 400,000 people live with the disease in the U.S., and about 200 new cases are diagnosed every week. As reported by Healthline Media in 2015, multiple sclerosis ranks second after congestive heart failure, with direct and indirect healthcare costs ranging from US$ 8,528 to US$ 54,244 per patient each year. However, higher therapy costs is a significant factor restraining the growth of the global multiple sclerosis therapeutics market.
Intensive R&D programs undertaken by organizations to accelerate the market growth
Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/multiple-sclerosis-therapeutics-market-to-surpass-us-244-billion-by-2025-604
Competitive Landscape
The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- Alternative Therapies
- Pipeline Analysis
- Supply Chain Analysis
- PEST Analysis
- Epidemiology
- Market Dynamics
- Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Oral
- Injection
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- Introduction
- Global Multiple Sclerosis Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
